靶动脉灌注维拉帕米联合化疗药物治疗非小细胞肺癌的临床研究
发布时间：2018-08-24 16:19
【摘要】：目的:观察靶动脉灌注维拉帕米及化疗药物对中晚期非小细胞肺癌(NSCLC)的有效率(CR+PR)和生存期的影响。方法:对NSCLC患者51例,经靶动脉灌注维拉帕米和化疗药物,每月介入治疗1次为1疗程,每例治疗2-4个疗程后,评估近期疗效,对51例中治疗后满3年的38例随访1、2、3年生存率。结果:51例中晚期NSCLC患者,评估近期疗效,完全缓解(CR)5例(9.80%),部分缓解(PR)36例(70.59%),总有效率(CR+PR)为80.39%。38例NSCLC患者评估远期疗效,中位生存时间为24.0月,l、2、3年生存率分别为76.3%(29/38)、55.3%(21/38)和26.3%(10/38);其中22例鳞癌中位无进展期时间为17.0月,13例腺癌中位无进展期时间为10.0月。在对51例患者的毒副反应评价中发现,15例患者(31.37%)出现白细胞下降,12例(23.53%)出现I-II级的消化道反应的不良反应。51例患者未见维拉帕米相关的心血管副作用。结论:靶动脉灌注维拉帕米联合化疗药物对于中晚期NSCLC患者的近期、远期疗效确切,部分患者可获得手术及根治性放疗的机会。无明显副作用,患者可耐受。可使部分患者肿瘤降期降级,能在一定程度上延长患者生存时间。
[Abstract]:Aim: to observe the effect of target artery infusion of verapamil and chemotherapeutic drugs on the effective (CR PR) and survival time of (NSCLC) in patients with advanced non-small cell lung cancer (NSCLC). Methods: a total of 51 patients with NSCLC were treated with verapamil and chemotherapeutic drugs via target artery. One course of interventional therapy was used once a month. After 2-4 courses of treatment, the short-term effect was evaluated. 38 cases of 51 patients with NSCLC were followed up for 1, 2 and 3 years after 3 years of treatment. Results in 51 cases of middle and late stage NSCLC, 5 cases (9.80%) had complete remission of (CR) and 36 cases (70.59%) had partial remission of (PR). The total effective rate of (CR PR) was 80.39%. 38 cases of NSCLC were evaluated for long-term curative effect. The median survival time was 24.0 months and the 3-year survival rate was 76.3% (29 / 38), 55.3% (21 / 38) and 26.3% (10 / 38), respectively, and the median non-progression time of 22 cases of squamous cell carcinoma was 17.0 months and 13 cases of adenocarcinoma was 10.0 months. Among 51 patients, 15 (31.37%) had leukocytopenia and 12 (23.53%) had I-II grade digestive tract reaction. There were no cardiovascular side effects associated with verapamil in 51 patients. Conclusion: the short-term and long-term curative effect of target artery infusion of verapamil combined with chemotherapeutic drugs in patients with intermediate and advanced NSCLC is definite, and some patients can obtain the opportunity of operation and radical radiotherapy. No obvious side effects, the patient can tolerate. It can reduce the tumor stage and prolong the survival time to some extent.
【学位授予单位】：皖南医学院
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R734.2
本文编号：2201355
[Abstract]:Aim: to observe the effect of target artery infusion of verapamil and chemotherapeutic drugs on the effective (CR PR) and survival time of (NSCLC) in patients with advanced non-small cell lung cancer (NSCLC). Methods: a total of 51 patients with NSCLC were treated with verapamil and chemotherapeutic drugs via target artery. One course of interventional therapy was used once a month. After 2-4 courses of treatment, the short-term effect was evaluated. 38 cases of 51 patients with NSCLC were followed up for 1, 2 and 3 years after 3 years of treatment. Results in 51 cases of middle and late stage NSCLC, 5 cases (9.80%) had complete remission of (CR) and 36 cases (70.59%) had partial remission of (PR). The total effective rate of (CR PR) was 80.39%. 38 cases of NSCLC were evaluated for long-term curative effect. The median survival time was 24.0 months and the 3-year survival rate was 76.3% (29 / 38), 55.3% (21 / 38) and 26.3% (10 / 38), respectively, and the median non-progression time of 22 cases of squamous cell carcinoma was 17.0 months and 13 cases of adenocarcinoma was 10.0 months. Among 51 patients, 15 (31.37%) had leukocytopenia and 12 (23.53%) had I-II grade digestive tract reaction. There were no cardiovascular side effects associated with verapamil in 51 patients. Conclusion: the short-term and long-term curative effect of target artery infusion of verapamil combined with chemotherapeutic drugs in patients with intermediate and advanced NSCLC is definite, and some patients can obtain the opportunity of operation and radical radiotherapy. No obvious side effects, the patient can tolerate. It can reduce the tumor stage and prolong the survival time to some extent.
【学位授予单位】：皖南医学院
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R734.2
【参考文献】
相关期刊论文 前10条
1 刘华丽;胡伟国;宋启斌;;Ⅲ期非小细胞肺癌非手术治疗的现状与研究进展[J];肿瘤学杂志;2016年02期
2 魏家玮;郭述良;;支气管动脉灌注化疗与全身静脉化疗对晚期非小细胞肺癌患者疗效及不良反应发生率的META分析[J];中华肺部疾病杂志(电子版);2015年03期
3 李跃军;卓德斌;;ABCG2、MDR1基因表达水平与5-氟尿嘧啶耐药的CD44+SGC-7901/5-Fu多药耐药关系[J];中国老年学杂志;2014年18期
4 梁丽峰;戢福云;马李杰;赵诣林;陈向军;金发光;;肺癌获得性多药耐药机制的研究进展[J];国际呼吸杂志;2014年14期
5 赵真真;王忠敏;茅爱武;;非小细胞肺癌的介入治疗现状[J];介入放射学杂志;2014年03期
6 袁红;陆舜;;肺鳞癌靶向治疗研究现状[J];中国肺癌杂志;2013年10期
7 朱磊;段巧虹;范平生;李继德;童少明;俞修坤;魏强;;靶动脉灌注维拉帕米对晚期食管癌介入疗效的临床观察[J];安徽医学;2011年11期
8 刘亚贝;李烨;唐艳;陈曼萍;胡冰;林新民;鲁朝晖;范平生;;维拉帕米联合化疗药物治疗恶性胸腹水的临床观察[J];安徽医药;2010年04期
9 刘颖;王丽莉;;米非司酮调控卵巢癌细胞表达葡萄糖神经酰氨合成酶并逆转其多药耐药性[J];南方医科大学学报;2008年09期
10 肖湘生;董生;董伟华;张电波;李相生;史景云;;肺癌血供系列研究[J];介入放射学杂志;2008年03期
，本文编号：2201355
本文链接：https://www.wllwen.com/yixuelunwen/zlx/2201355.html
